Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHA:600329)

China flag China · Delayed Price · Currency is CNY
46.49
+0.12 (0.26%)
At close: Dec 5, 2025
46.38%
Market Cap31.07B
Revenue (ttm)5.37B
Net Income (ttm)3.58B
Shares Out770.09M
EPS (ttm)4.66
PE Ratio9.98
Forward PE15.39
Dividend1.28 (2.75%)
Ex-Dividend DateJul 4, 2025
Volume2,992,804
Average Volume5,233,651
Open46.36
Previous Close46.37
Day's Range46.00 - 46.55
52-Week Range28.53 - 50.97
Beta0.87
RSI52.28
Earnings DateMar 31, 2026

About SHA:600329

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited engages in the research, development, processing, manufacturing, and sale of traditional Chinese medicine in China. It provides pharmaceutical products for cardiovascular and cerebrovascular, skin wound repair, health preservation, respiratory, digestion, rheumatism and osteodynia, urological, gynecological and pediatric, ophthalmological, tumor, chronic, and other diseases, as well as tonic drugs. The company was formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Li... [Read more]

Sector Healthcare
Founded 1981
Employees 4,619
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 600329
Full Company Profile

Financial Performance

In 2024, SHA:600329's revenue was 7.31 billion, a decrease of -11.14% compared to the previous year's 8.22 billion. Earnings were 2.23 billion, an increase of 125.94%.

Financial Statements

News

There is no news available yet.